English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, July 30, 2021
エーザイとバイオジェン、Lecanemab(BAN2401)の臨床効果についてアルツハイマー病協会国際会議2021(AAIC2021)のLate Breakingとして発表
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer's Disease at AAIC 2021
Thursday, July 29, 2021
Eisai Listed for 20th Consecutive Year in FTSE4Good Index Series, An Index for Socially Responsible Investment
Tuesday, July 27, 2021
バイオジェンとエーザイ、ADUHELM(TM)の最新データをアルツハイマー病協会国際会議2021(AAIC2021)において発表
Biogen and Eisai Announce ADUHELM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021
Monday, July 26, 2021
エーザイ、「レンビマ(R)」(レンバチニブ)と「キイトルーダ(R)」(ペムブロリズマブ)の併用療法について進行性子宮内膜がんに係る承認を米国FDAより取得
Friday, July 23, 2021
Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
Wednesday, July 21, 2021
Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021
エーザイのアルツハイマー病/認知症領域の開発品に関する最新データをアルツハイマー病協会国際会議 2021(AAIC2021)にて発表
Monday, July 19, 2021
エーザイ、米国におけるADUHELM(TM)の状況について発表

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575